araag2/HINT huggingface dataset:
Clinical trial NCT02045017 (phase 2, status: active, not recruiting)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: pomalidomide and dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

        - Subjects must satisfy the following criteria to be enrolled in the study.

        1. Subjects must have documented diagnosis of multiple myeloma and have measurable disease
        (serum M-protein ≥ 0.5 g/dL or urine M-protein ≥ 200 mg/24 hours).

        5. Subjects must have had at least 1 prior antimyeloma regimen including lenalidomide and
        documented progression as per the International Myeloma Working Group uniform response
        criteria (Durie, 2006) during or after the last antimyeloma regimen. Induction therapy
        followed by Autologous Stem Cell Transplant and consolidation/ maintenance will be
        considered as one regimen.

        6. Subjects must have an impaired renal function with an estimated Glomerular Filtrate Rate
        of < 45 mL/min/1.73 m2 according to the modification of diet in renal disease equation.

          1. Impaired renal function must be due to multiple myeloma which needs to be confirmed by
             kidney biopsy.

          2. Subjects may have acute myeloma related renal failure or chronic myeloma related renal
             failure; they may also have been treated with dialysis before, including dialysis with
             high cut off membranes.

        Exclusion Criteria:

        The presence of any of the following will exclude a subject from enrollment

          1. Any significant medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from participating in the study.

          2. Any condition including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study.

          3. Renal insufficiency due to other reasons than multiple myeloma or due to hypocalcaemia
             only.

          4. Prior history of malignancies, other than MM, unless the subject has been free of the
             disease for ≥ 5 years; exceptions include the following:

               1. Basal or squamous cell carcinoma of the skin

               2. Carcinoma in situ of the cervix or breast

               3. Incidental histological finding of prostate cancer (Tumour lymphNode Metastasis
                  stage of T1a or T1b)

        6. Previous therapy with pomalidomide. 7. Hypersensitivity to thalidomide, lenalidomide, or
        dexamethasone (this includes ≥ Grade 3 rash during prior thalidomide or lenalidomide
        therapy).

        10. Subjects who are planning for or who are eligible for stem cell transplant.
Clinical trial NCT02045277 (phase 2, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: idp-118 lotion, idp-118 monad hp lotion, idp-118 monad taz lotion, idp-118 vehicle lotion
SMILES: [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female, of any race, at least 18 years of age (inclusive).

          -  Freely provides both verbal and written informed consent.

          -  Has an area of plaque psoriasis appropriate for topical treatment that covers a BSA of
             at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae and
             intertriginous areas are to be excluded in this calculation.

          -  Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet
             radiation (natural and artificial) for the duration of the study.

          -  Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or
             4. (The face, scalp, palms, soles, axillae and intertriginous areas are to be excluded
             in this assessment, if psoriasis is present).

        Key Exclusion Criteria:

          -  Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular
             psoriasis, as determined by the investigator.

          -  Presents with psoriasis that was treated with prescription medication and failed to
             respond to treatment, even partially or temporarily, as determined by the
             investigator.

          -  Presents with any concurrent skin condition that could interfere with the evaluation
             of the treatment areas, as determined by the investigator.

          -  Is pregnant, nursing an infant, or planning a pregnancy during the study period.

          -  Has received treatment with any investigational drug or device within 60 days or 5
             drug half lives (whichever is longer) prior to the Baseline visit, or is concurrently
             participating in another clinical study with an investigational drug or device.
Clinical trial NCT02048618 (phase 2, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: glpg0634, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects between 18 and 75 years

          -  Documented history of ileal, colonic, or ileocolonic CD

          -  CDAI score ≥ 220 to ≤ 450

          -  Evidence of active inflammation as demonstrated by endoscopic confirmation of active
             disease

          -  Subjects previously not exposed to anti-TNF treatment (TNF-naïve) or subjects
             previously exposed to anti-TNF therapy at a registered dose, that has been
             discontinued at least 8 weeks prior to Screening and deemed by the treating physician
             as a primary or secondary non-responder or intolerant (TNF-experienced)

          -  Continuation of concurrent treatment with oral steroids (≤30 mg prednisolone eq/day),
             mesalazine, olsalazine, CD-related antibiotics and probiotics at stable dose is
             allowed

          -  Previous exposure to immunomodulators is permitted, but must be discontinued

          -  Haematology and biochemistry lab parameters within predefined ranges as stated in the
             protocol

        Exclusion Criteria:

          -  Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings
             suggestive of UC

          -  Stoma, gastric or ileoanal pouch, procto- or total colectomy, symptomatic stenosis or
             obstructive strictures, history of bowel perforation, (suspected) abscess; actively
             draining fistulae

          -  Subject who has had surgical bowel resections within the past 6 months, short bowel
             syndrome or is receiving tube feeding, defined formula diets, or parenteral
             alimentation

          -  Subject with positive Clostridium difficile toxin stool assay or evidence of any other
             gastrointestinal infection

          -  Subject who has received non-permitted IBD therapies within specified timeframes,
             depending on the medication, as stated in the protocol

          -  Subject with a (previous history of) dysplasia of the gastrointestinal tract

          -  Concurrent gastro-intestinal malignancy or a history of cancer elsewhere

          -  History of lymphoproliferative disease

          -  Known active infection of any kind, current therapy for chronic infection or history
             of specific infections as stated in the protocol

          -  Subject who is pregnant, lactating or not willing to maintain highly effective birth
             control methods during the course of the study and 12 weeks thereafter
Clinical trial NCT02048865 (phase 2, status: completed)
Conditions: venous thromboembolism, cancer
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: apixaban, placebo drug
SMILES: COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  A newly diagnosed cancer site or progression of the malignant disease after complete
             or partial remission.

          -  Initiating a new course of chemotherapy with a minimum intent of 3 months therapy

          -  A VTE risk stratification score of ≥ 2, according to the scoring method

          -  Age 18 years old or older

          -  Provide written informed consent

        Exclusion Criteria:

          -  Lesions or conditions at increased risk of clinically significant bleeding (eg. active
             peptic ulcer disease)

          -  Objectively confirmed substantial liver insufficiency as defined by clinical
             manifestations of ascites, cirrhosis, encephalopathy and/or jaundice and/or
             biochemical abnormalities in liver function tests including hypoalbuminemia (< 3.5
             gr/dL), elevated levels of total bilirubin (> 25 umol/L), elevated liver transaminases
             (2 times the upper limit of normal) and/or biochemical diagnosis of biliary tract
             obstruction (elevated levels of gamma-glutamyl transferase and alkaline phosphatase, 3
             times the upper limit of normal). *

          -  Diagnosis of basal cell or squamous cell carcinoma of the skin or acute leukemia or
             myelodysplastic syndrome**

          -  Planned stem cell transplant

          -  Life expectancy less than 6 months

          -  Acute or chronic renal insufficiency with glomerular filtration rate (GFR) < 30 ml/min
             calculated by the Cockroft and Gault formula.

          -  Pregnancy***

          -  Continuous anticoagulation with vitamin K antagonists, low-molecular-weight heparin
             (LMWH), or other oral anticoagulants

          -  Weight < 40 Kg

          -  Platelet count < 50 x 109/L

          -  Known allergies to ingredients contained in apixaban

          -  Use of any contraindicated medications with apixaban
Clinical trial NCT02049450 (phase 2, status: completed)
Conditions: thalassemia major
ICD codes: D56.0, D56.1, D56.3, D56.9, D56.2, D56.5, D57.40
Drugs: ruxolitinib
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with thalassemia on a regular and stable transfusion regimen (at least 2 RBC
             units within every 4-week interval for 24 weeks prior to Screening) and anticipated to
             receive the same transfusion regimen during the study.

          -  Patients with spleen enlargement at Screening, defined as spleen palpable below the
             costal margin and spleen volume of ≥ 450 cm3 as confirmed by MRI (or CT scan in
             applicable patients).

          -  Patients need to be on iron chelation treatment (deferoxamine or deferasirox) for at
             least four weeks prior to Screening

        Exclusion Criteria:

          -  Splenectomy prior to or planned during the study

          -  Active serious bacterial, mycobacterial, fungal, parasitic or viral infection which
             requires therapy (e.g., pneumonia, tuberculosis, systemic mycosis, herpes zoster)

          -  Hemoglobin <65 g/L (<4.0 mmol/L) at Screening

          -  Platelet count <75×109/L, absolute neutrophils count < 1.5×109/L at Screening.

          -  Estimated MDRD < 30 mL/min/1.73 m2 at Screening.

          -  ALT (SGPT) levels >5 times ULN at Screening.

          -  Hepatocellular disease such as hepatitis B (presence of HBs antigen), hepatitis C
             (presence of HCV RNA), liver cirrhosis.

          -  HIV positivity
Clinical trial NCT02054052 (phase 2, status: completed)
Conditions: non-small cell lung cancer, malignant pleural effusion
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Histological or cytological diagnosis of non-small cell lung cancer.

          2. Cytological diagnosis of malignant pleural or pericardial effusion (MPE)

          3. Symptomatic MPE evaluated by researchers

          4. Unsuitable for or reject systemic therapy of tumor

          5. Estimated survival of more than 3 months. 6.18 years or older

        Exclusion Criteria:

          1. Current or recent (within 10 days prior to treatment) use the full amount of
             inhibition of platelet function, anticoagulants or thrombolytic therapy, which allows
             prophylactic anticoagulants

          2. Be allergic to bevacizumab

          3. Pregnant or lactating woman

          4. Pleural or pericardial infection
Clinical trial NCT02055170 (phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: finasteride 5mg oral daily
SMILES: [H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C
Reason stopped: 
    unable to improve on poor accrual to study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  male

          -  age >18

          -  biopsy-proven non-small cell lung cancer

          -  surgical intervention planned

        Exclusion Criteria:

          -  current use of 5-alpha reductase inhibitor

          -  previous diagnosis of prostate cancer

          -  previous hypersensitivity to 5-alpha reductase inhibitor
Clinical trial NCT02055976 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: bococizumab (pf-04950615;rn316), bococizumab (pf-04950615;rn316), bococizumab (pf-04950615;rn316), placebo, ezetimibe, bococizumab (pf-04950615;rn316), bococizumab (pf-04950615;rn316), bococizumab (pf-04950615;rn316), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects whose LDL-C is not controlled by a stable dose of atorvastatin (Population
             A).

          -  Subjects who are naïve to a treatment by lipid lowering drug and whose LDL-C is not
             controlled (Population B).

        Exclusion Criteria:

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality.

          -  Pregnant females; breastfeeding females; males and females of childbearing potential;
             males and females of childbearing potential who are unwilling or unable to use a
             highly effective method of contraception.

          -  Subjects who were administered or prior exposed to PF-04950615 and/or anti-body
             targeting PCSK9.
Clinical trial NCT02057172 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: hm11260c, liraglutide, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ages eligible for study : 18 years to 74 years

          -  Genders eligible for study : Male and Female

          -  Diagnosed with T2DM

          -  Received diet and exercise therapy with or without metformin monotherapy

          -  HbA1c levels of between ≥ 7.0% and ≤ 10.0%

          -  Females of childbearing potential who are not pregnant and agree to use a reliable
             method of birth control

          -  Written informed consent must be obtained

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women

          -  Diagnosis of type 1 diabetes mellitus

          -  Uncontrolled diabetes defined as a FPG level of > 240 mg/dL

          -  A significant change in body weight in the 3 months before screening

          -  Any history of GI intolerance

          -  Personal or family history of medullary thyroid cancer (MTC) or a genetic condition
             that predisposes to MTC

          -  Known history of chronic pancreatitis

          -  A history of alcohol or drug abuse or drug addiction
Clinical trial NCT02057380 (phase 2, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: linsitinib, erlotinib, paclitaxel, bortezomib, dexamethasone
SMILES: C[C@@]1(O)C[C@@H](C1)C1=NC(=C2N1C=CN=C2N)C1=CC=C2C=CC(=NC2=C1)C1=CC=CC=C1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must currently be participating in an Astellas sponsored linsitinib trial that
             has ended with respect to the overall study analysis.

          -  Subject must not have met criteria for discontinuation or have progressed on the
             current linsitinib study in which they are participating.

          -  Subject must be deriving benefit from continued treatment.
Clinical trial NCT02057575 (phase 2, status: completed)
Conditions: open angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: pg324 ophthalmic solution 0.01%, pg324 ophthalmic solution 0.02%, netarsudil (ar-13324) ophthalmic solution 0.02%, latanoprost ophthalmic solution 0.005%
SMILES: CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or greater.

          -  Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT)

          -  Corrected visual acuity in each eye equivalent to 20/200 or better

          -  Able and willing to give signed informed consent and follow study instructions.

        Exclusion Criteria:

        Ophthalmic:

          -  Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure,
             or narrow angles.

          -  Intraocular pressure >36 mmHg

          -  Known hypersensitivity to any component of the formulation, latanoprost, or to topical
             anesthetics.

          -  Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s)

          -  Refractive surgery in study eye(s)

          -  Ocular trauma within the six months prior to screening, or ocular surgery or laser
             treatment within the three months prior to screening.

          -  Evidence of ocular infection and inflammation

          -  Clinically significant ocular disease, which might interfere with the study, including
             glaucomatous damage so severe that washout of ocular hypotensive medications for one
             month is not judged safe

          -  Central corneal thickness greater then 600 μm

          -  Any abnormality preventing reliable applanation tonometry of either eye

        Systemic:

          -  Clinically significant abnormalities (as determined by the investigator) in laboratory
             tests at screening.

          -  Clinically significant systemic disease

          -  Participation in any investigational study within 30 days prior to screening

          -  Changes in systemic medication

          -  Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or
             not using a medically acceptable form of birth control.
Clinical trial NCT02061007 (phase 2, status: withdrawn)
Conditions: melanoma, skin cancer
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, C79.2, C44.500, C44.90, D23.9, D48.5, C44.00, C44.301
Drugs: pimonidazole hydrochloride (hypoxyprobe™-1), optional 18f-fmiso pet scan (18f-fluoromisonidazole)
SMILES: OC(CN1C=CN=C1[N+]([O-])=O)CN1CCCCC1
Reason stopped: 
    no accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Must be 18 years or older with a histological diagnosis of locally advanced, recurrent
             or metastatic melanoma and be scheduled for clinically indicated surgical removal of
             one or more melanoma tumors. Additionally, patients must have a resectable tumor
             nodule ≥1 cm^3 (i.e., either a spherical tumor at least 1.0 cm in diameter or a tumor
             measuring at least 1x1x1 cm). Prior biopsy is not required for study participation.

          -  Not pregnant or nursing (as confirmed by serum pregnancy test if the patient is a
             woman of child-bearing potential). Participants must agree with use birth control for
             30 days following pimonidazole administration.

          -  Adequate kidney and liver function as assessed by laboratory studies

          -  Must be able to undergo magnetic resonance imaging (MRI) scans

          -  Capable of providing informed consent and demonstrate a willingness to comply with all
             the study procedures and visits

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 -1

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Patients who are contraindicated for MRI or gadolinium contrast agents due to:

               -  Presence of metallic objects or implanted medical devices in body (i.e., cardiac
                  pacemaker, aneurysm clips, surgical clips, prostheses, skin staples, implanted
                  prostheses, artificial heart valves with steel parts, metal fragments, shrapnel,
                  or other metal implants that would contraindicate MRI)

               -  Sickle cell disease

               -  Renal failure with estimated glomerular filtration rate (eGFR) < 30
                  mL/min/1.73m^2 based upon serum creatinine

               -  Weight greater than 350 lbs (the weight limit for the MRI)

          -  Patients with known, active (i.e. not adequately treated with curative intent)
             malignancies other than melanoma

          -  Presence of any other co-existing condition which, in the judgment of the
             investigator, might increase the risk to the participant